Justification for the selection of a candidate CoRAP substance

Substance Name (Public

methyl 4-hydroxybenzoate Name):

Chemical Group:

EC Number: 202-785-7

CAS Number: 99-76-3

Submitted by: **FRANCE**

Published: 20/03/2013

NOTE

This document has been prepared by the evaluating Member State given in the CoRAP update.

Contents

1	IDENTITY OF THE SUBSTANCE	3
	1.1 Name and other identifiers of the substance	3
2	CLASSIFICATION AND LABELLING	4
	2.1 Harmonised Classification in Annex VI of the CLP	4
	2.2 Self classification	4
3	JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE	5
	3.1 Legal basis for the proposal	5
	3.2 Grounds for concern	5
	3.3 Information on aggregated tonnage and uses	5
	3.4 Other completed/ongoing regulatory processes that may affect suitability for substant evaluation	
	3.5 Information to be requested to clarify the suspected risk	6
	3.6 Potential follow-up and link to risk management	6

1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity

Public Name:	methyl 4-hydroxybenzoate
EC number:	202-785-7
EC name:	methyl 4-hydroxybenzoate
CAS number (in the EC inventory):	99-76-3
CAS number:	99-76-3
CAS name:	Benzoic acid, 4- hydroxy-, methyl ester
IUPAC name:	methyl 4-hydroxybenzoate
Index number in Annex VI of the CLP Regulation	-
Molecular formula:	C8H8O3
Molecular weight or molecular weight range:	152.14 g/mol
Synonyms:	4-hydroxybenzoic_acid,_methyl_ester
	Benzoic acid, 4-hydroxy-, methyl ester

Type of substance: ✓ Mono-constituent □	Multi-constituent	UVCB
---	-------------------	------

Structural formula:

2 CLASSIFICATION AND LABELLING

2.1 Harmonised Classification in Annex VI of the CLP

None

2.2 Proposal for Harmonised Classification in Annex VI of the CLP

None

2.3 Self classification

The registration data includes the following self classification: None

<u>In addition are the following classification(s) included in the Classification and Labelling Inventory:</u>

Skin Irrit. 2, H315: Causes skin irritation

Eye Irrit. 2, H319: Causes serious eye irritation

STOT SE 3, H335: May cause respiratory irritation

Muta. 2 H341 H341: Suspected of causing genetic defects

Acute Tox. 4 H302: Harmful if swallowed

Resp. Sens. 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled

Skin Sens. 1 H317: May cause an allergic skin reaction

Aquatic Chronic 3 H412: Harmful to aquatic life with long lasting effects

3 JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

3.1 Legal basis for the proposal

Article 44(1) (refin	ed prioritisation	criteria for	substance	evaluation)
C Article 45(5) (Mea	mber State prior	ity)		

3.2 Grounds for concern

☐ (Suspected) CMR	☐ Wide dispersive use	☐ Cumulative exposure		
☐ (Suspected) Sensitiser	⊠ Consumer use	☐ High RCR		
☐ Suspected PBT	Exposure of sensitive populations	Aggregated tonnage		
✓ Suspected endocrine disruptor ☐ Other (provide further details below)				
According to DHI study (Petersen et al., 2007) on enhancing the ED priority list focus on LPV chemicals:				
The substance is readily biodegr	radable and has a low potential for bi	oaccumulation (EUSES).		
A high direct human exposure is expected.				
Human health: Cat 1 (At least one study providing evidence of endocrine disruption in an intact organism. Not a formal weight of evidence approach).				
Wildlife: Cat 3b (substance with no or insufficient data gathered).				
Overall categorization: Cat 1.				
Classification from the notification (Muta. 2 and Resp. Sens 1. in particular) need to be checked.				

3.3 Information on aggregated tonnage and uses

□ 1 - 10 t	□ 10 - 100 t	□ 100 - 1000 t	▼ 1000 - 10,000 t	
10,000 - 100,000 t	□ 100,000 - 1000,000 t	> 1000,000 t	Confidential	

JUSTIFICATION DOCUMENT FOR THE SELECTION OF A CORAP SUBSTANCE

✓ Industrial Use	☐ Professional Use	▼ Consumer Use	Closed System		
-	oleted/ongoing r or substance eva	egulatory processe	s that may affect		
☐ Compliance check		☐ Annex VI (CLP)			
☐ Testing Proposal(s)		☐ Annex XIV (Authorisation)			
☐ Substance Identification	n Issues	☐ Annex XVII (Restriction)		
☐ ESR Programme		☐ Other (provide further de	etails below)		
Not known at this stag	e				
3.5 Information	n to be requested	I to clarify the susp	ected risk		
✓ Information on toxicole	ogical properties	✓ Information on exposure			
☐ Information on fate and	d behaviour	✓ Information on uses			
☐ Information on ecotoxi	icological properties	☐ Other (provide further details below)			
☐ Information on physico	o-chemical properties				
Exact information requ	Exact information required to be determined during the substance evaluation.				
3.6 Potential follow-up and link to risk management					
☐ Restriction	☐ Harmonised C&L				
☐ Authorisation	☐ Authorisation ☐ Other (provide further details below)				
Depends on the outcome of substance evaluation					

EC no. 202-785-7 MSCA - France Page 6 of 6